On Demand Pharmaceuticals Commissions State-of-the-Art, cGMP Medicine Manufacturing Facility
The CGMP facility represents a critical first step in a new era of drug manufacturing aimed at strengthening domestic supply chain resiliency
The CGMP facility represents a critical first step in a new era of drug manufacturing aimed at strengthening domestic supply chain resiliency
Summa Equity Fund II (“Summa”) has acquired a majority stake in G-CON, a leading US-based manufacturer of prefabricated cleanrooms used for manufacturing within the pharmaceuticals industry. G-CON designs, builds and installs turnkey cGMP (Current Good Manufacturing Practice) compliant suites called PODs, for a global biopharma customer base focused on biologics, pharma, CDMO (contract development and manufacturing), and cell and gene therapy manufacturing.